Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18101266 | 1.00 | CMA1 (0.51) | CMA1KDM4EMAPTLMNAHTT | |
| SCHEMBL18101221 | 1.00 | CMA1 (0.51) | CMA1KDM4EMAPTLMNAHTT | |
| SCHEMBL18101274 | 1.00 | CMA1 (0.51) | CMA1KDM4EMAPTLMNAHTT | |
| SCHEMBL13820085 | 0.95 | CMA1 (0.56) | CMA1KDM4EMAPTALDH1A1GAA | |
| SCHEMBL29510602 | 0.76 | CMA1 (0.58) | CMA1KDM4EMAPTALDH1A1GAA | |
| SCHEMBL28752534 | 0.76 | CMA1 (0.58) | CMA1KDM4EMAPTALDH1A1GAA | |
| SCHEMBL21389665 | 0.76 | ALDH1A1 (0.35) | CMA1KDM4EMAPTALDH1A1GAA | |
| SCHEMBL21389656 | 0.76 | KDM4E (0.43) | KDM4EMAPTLMNAHTTBLM | |
| SCHEMBL15981859 | 0.73 | DRD2 (0.52) | KDM4EMAPTLMNAHTTBLM | |
| SCHEMBL15981860 | 0.73 | DRD2 (0.52) | KDM4EMAPTLMNAHTTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190293667-A1 | Solid Phase Extraction, Derivatization with Crown Ethers, and Mass Spectrometry, Methods, Reagents and Kits | TECAN SP, INC. (US) | 2019-09-26 | — | — | US | disclosed |
| US-20160282371-A1 | Solid Phase Extraction, Derivatization with Crown Ethers, and Mass Spectrometry, Methods, Reagents and Kits | QUANTALYTICAL LABS INC. (US) | 2016-09-29 | — | — | US | disclosed |
| US-20160282371-A1 | Solid Phase Extraction, Derivatization with Crown Ethers, and Mass Spectrometry, Methods, Reagents and Kits | QUANTALYTICAL LABS INC. (US) | 2016-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190293667-A1 | Solid Phase Extraction, Derivatization with Crown Ethers, and Mass Spectrometry, Methods, Reagents and Kits | CYP2C8, CES2, UGT1A8 | CMA1 2111/4885KDM4E 152/4885MAPT 2114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.